Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 29;13(2):225-235.
doi: 10.21037/gs-23-453. Epub 2024 Feb 20.

Perspectives on surgical treatment for thymic epithelial tumors: a narrative review

Yusuke Nabe  1 , Masaaki Inoue  1 , Junichi Yoshida  1
Affiliations
Review

Perspectives on surgical treatment for thymic epithelial tumors: a narrative review

Yusuke Nabe et al. Gland Surg. .

Abstract

Background and objective: Thymic epithelial tumors are relatively rare; thus, mostly retrospective studies and a few prospective randomized controlled trials have been conducted on the treatment and the biomarkers, with no standard therapy established. Indications for extended thymectomy, robot-assisted thoracic surgery, and multidisciplinary treatment are controversial. Here, we considered the prospects of surgical treatment and the possibility of immune checkpoint inhibitor (ICI) treatment for thymic epithelial tumors.

Methods: This is a narrative review; PubMed was searched using a set of keywords related to thymoma and its proposed treatments over the last 5 years.

Key content and findings: Thymic epithelial tumors are associated with autoimmune diseases. They are relatively rare, and their pathology remains unclear. Therefore, accumulating more case reports is important. Surgical resection is generally considered for both diagnosis and treatment. If the tumor has a strong tendency to invade surrounding areas, such as thymic carcinoma/thymoma, the diagnosis may be confirmed preoperatively by needle biopsy, and induction chemotherapy may be selected. Surgical resection is the most effective treatment, and complete resection is important. In cases where complete resection is difficult, multidisciplinary treatment is performed. Although there are various obstacles, using ICIs may prove effective for treatment both as preoperative and postoperative chemotherapy in the future, as shown for other cancers. Programmed cell death-ligand 1 (PD-L1) is an immunoinhibitory molecule that suppresses T cells activation, leading to tumor progression. Overexpression of PD-L1 in some cancers is associated with poor clinical outcomes. However, the role of PD-L1 expression as a prognostic factor remains controversial. Therefore, various biomarkers other than PD-L1 have been identified.

Conclusions: We reviewed the latest treatments for thymic epithelial tumors. If new therapeutic agents such as ICIs and molecular-targeted drugs are developed, this review suggests that surgery will become more important not only as therapy but also as part of multidisciplinary treatment that includes tissue collection.

Keywords: Extended thymectomy; immune checkpoint inhibitor (ICI); multidisciplinary treatment; surgery; thymoma.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://gs.amegroups.com/article/view/10.21037/gs-23-453/coif). J.Y. served as the principal investigator for Insmed Inc. and Janssen Pharmaceutical. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Inclusion and exclusion criteria.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ruan H, Liu B, Yang X, et al. Analysis of Pulmonary Function in Thymoma Subjects: A 20-Year Retrospective Cohort Study. Thorac Cardiovasc Surg 2023;71:425-31. 10.1055/s-0042-1749320 - DOI - PMC - PubMed
    1. Yang F, Dai J, Lou X, et al. Prognostic factors and role of postoperative radiotherapy in surgically resected thymomas. JTCVS Open 2023;14:561-80. 10.1016/j.xjon.2023.02.013 - DOI - PMC - PubMed
    1. Tartarone A, Lerose R, Lettini AR, et al. Current Treatment Approaches for Thymic Epithelial Tumors. Life (Basel) 2023;13:1170 .10.3390/life13051170 - DOI - PMC - PubMed
    1. Nakamura S, Kawaguchi K, Fukui T, et al. Multimodality therapy for thymoma patients with pleural dissemination. Gen Thorac Cardiovasc Surg 2019;67:524-9. 10.1007/s11748-018-01054-7 - DOI - PubMed
    1. Tichet M, Wullschleger S, Chryplewicz A, et al. Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8(+) T cells and reprogramming macrophages. Immunity 2023;56:162-179.e6. 10.1016/j.immuni.2022.12.006 - DOI - PubMed